Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (61-70 of 231) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|January 8, 2020
Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemiaSarah A Buckley, Anna B Halpern, Megan Othus, et al.
Journal of Medical Economics|December 18, 2020
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancerJoshua A Roth, Yong Yuan, Megan Othus, et al.
Leukemia & Lymphoma|January 13, 2016
Prediction of early death in adults with relapsed or refractory acute myeloid leukemiaColin D Godwin, Megan Othus, Morgan A Powell, et al.
Leukemia & Lymphoma|March 15, 2021
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemiaMegan Othus, Guillermo Garcia-Manero, John Godwin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 1, 2024
Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing SubtypesNicole C Loroña, Megan Othus, Kathleen E Malone, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 29, 2023
Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast CancerNicole C Loroña, Megan Othus, Kathleen E Malone, et al.
Leukemia|October 14, 2018
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesMegan Othus, Mikkael A Sekeres, Sucha Nand, et al.
Research Square|April 1, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203Mary-Elizabeth Percival, Michelle Zhang, Megan Othus, et al.
Cancers|January 21, 2023
Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid LeukemiaCorentin Orvain, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Transplantation and Cellular Therapy|September 30, 2022
Relationship Between Pretransplantation Nutritional Status and Outcome in Adults with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationCorentin Orvain, Mariia Byelykh, Megan Othus, et al.
Pageof 24

Showing results (61-70 of 231) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|January 8, 2020
Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemiaSarah A Buckley, Anna B Halpern, Megan Othus, et al.
Journal of Medical Economics|December 18, 2020
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancerJoshua A Roth, Yong Yuan, Megan Othus, et al.
Leukemia & Lymphoma|January 13, 2016
Prediction of early death in adults with relapsed or refractory acute myeloid leukemiaColin D Godwin, Megan Othus, Morgan A Powell, et al.
Leukemia & Lymphoma|March 15, 2021
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemiaMegan Othus, Guillermo Garcia-Manero, John Godwin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 1, 2024
Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing SubtypesNicole C Loroña, Megan Othus, Kathleen E Malone, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 29, 2023
Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast CancerNicole C Loroña, Megan Othus, Kathleen E Malone, et al.
Leukemia|October 14, 2018
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesMegan Othus, Mikkael A Sekeres, Sucha Nand, et al.
Research Square|April 1, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203Mary-Elizabeth Percival, Michelle Zhang, Megan Othus, et al.
Cancers|January 21, 2023
Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid LeukemiaCorentin Orvain, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Transplantation and Cellular Therapy|September 30, 2022
Relationship Between Pretransplantation Nutritional Status and Outcome in Adults with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationCorentin Orvain, Mariia Byelykh, Megan Othus, et al.
Pageof 24